GHENT, Belgium, 2 July 2009 - Ablynx [Euronext Brussels: ABLX], a
pioneer in the discovery and development of Nanobodies®, a novel
class of antibody-derived therapeutic proteins, announced today its
promotion to the Belgian Mid-Cap Index (Bel Mid Index or BELMID) from
1 July 2009.
The entry of Ablynx to the Bel Mid Index is dependent upon Ablynx's
market capitalization, free float and velocity.
Dr. Edwin Moses, Chief Executive Officer and Chairman of Ablynx
commented: "The promotion of Ablynx to the Bel Mid Index is a
testament to the considerable progress Ablynx has made since our IPO.
We have a strong cash position and the financial turmoil over the
last year has not directly negatively affected Ablynx. We continue to
build and diversify our shareholder base, both domestically and
internationally. There are now three Nanobodies® in clinical
development and our lead programme, ALX-0081, a novel
anti-thrombotic, is on track to initiate Phase II during Q3. Earlier
this week, we announced that ALX-0061, our novel Nanobody® -based
therapeutic programme against IL6R, has entered preclinical
development for the treatment of autoimmune and inflammatory
diseases." Dr Moses added: "Our diverse product portfolio illustrates
the breadth of work across several therapeutic areas which is being
undertaken to exploit the significant potential of our Nanobody®
platform."
-ends-
For more information, please contact:
For international media enquiries: College Hill Life Sciences
Sue Charles, Justine Lamond,
Dr. John McIntyre
t: +44 (0)20 7866 7857
e: ablynx@collegehill.com
Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 /
+44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
http://hugin.info/137912/R/1326978/312528.pdf
Copyright © Hugin AS 2009. All rights reserved.
